Clinical trial · Observational
Serum Endocan Levels in Polycystic Ovary Syndrome
Serum Endocan Levels in Polycystic Ovary Syndrome: a Possible Marker of Angiogenic Dysfunction
NCT03019679CI-TRIAL-00049759completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study the investigators aimed to investigate whether there is a relation between polycystic ovary syndrome and serum endocan levels.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Study group
- description
- Patients with polycystic ovary syndrome
- label
- Control group
- description
- Patients without polycyctic ovary syndrome
Primary outcomes (1)
- measure
- Serum endocan level and its relationship with Polycystic Ovary Syndrome
- timeFrame
- 3 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * 18 to 45 years * Patients diagnosed with PCOS according to Rotterdam criteris (for the study group) * Patients without PCOS and menstrual irregularities (for the control group) * Absence of significant abnormalities on physical examination except hirsutism * No lipid lowering, hypoglycemic, antihypertensive or hormone replacement therapy * Normal thyroid function and prolactin level * Absence of history or evidence of metabolic, cardiovascular, respiratory or hepatic disease Exclusion Criteria: * Pregnant * Ovarian tumors * Endocrine diseases (Cushing disease, 21-Hydroxylase enzyme deficiency, thyroid dysfunction,hyperprolactinemia,diabetes) * Chronic diseases (renal insufficiency, cardiovascular, hepatic disease) * Oral contraceptive use, anti-androgenic,glucocorticoid, anti-hypertansive- anti-diabetic drug use * Smoking or alcohol use
References
Publications (0)
Data not yet available
No reference posted for this study.